John Vandermosten

Spectral AI receives FDA De Novo Clearance for DeepView Burn *$MDAI may now begin commercial distribution in the US finance.yahoo.com/sectors/health…

CEO Richard Christopher describes where Lexaria has done the most work in the GLP-1 agonist space, combining both injectable API and crushed oral tablets with DehydraTECH. $LEXX #OralGLP1 #OralDeliveryTech #GLP1Agonist #GLP1Innovation #MetabolicTherapy youtube.com/shorts/sG7Xj3G…

@syndevrx Chief Business Officer Jim Shanahan identifies several endpoints in the Aretha & Amelia studies. The trials are evaluating breast cancer patients & measuring insulin resistance, progression free survival & quality of life. #BioPharma #EmergingBiotech youtube.com/shorts/coy_9BB…

@LexariaBioCorp CEO Richard Christopher highlights one of the most important drawbacks of GLP-1 agonists…the side effect profile. Many suffer from uncomfortable GI issues which DehydraTECH formulations may reduce. $LEXX youtube.com/shorts/ir15Zic…

Cardiff Oncology filed suit vs Nerviano Medical Sciences, who provides the license for onvansertib *Disputes claim that $CRDF breached license agreement *Seeks order for Nerviano to perform according to its agreement investors.cardiffoncology.com/static-files/1…

@BioLineRx_Ltd to report 1Q 27May *Call @ 8:30 am ET *CEO Phil Serlin presiding $BLRX finance.yahoo.com/sectors/health…

@achievelifesci provides safety data from 52 weeks of cytisinicline treatment *Given today @ the American Thoracic Society meeting *Included smokers, vapers & dual users *Nausea incidence of 2.5% vs 30% for varenicline (see label) $ACHV achievelifesciences.com/achieve-presen…

Catch Lexaria's CEO Richard Christopher as he discusses Human Pilot Study #7. youtube.com/shorts/W9VXzLk…

@LexariaBioCorp receives Independent Review Board approval to begin Human Pilot Study #7. Compares DehydraTECH formulations of semaglutide against Wegovy tablets. $LEXX finance.yahoo.com/sectors/health…

@BioLineRx_Ltd & Hemispherian announce new GLIX1 data in glioblastoma *Preclinical anti-tumor activity *GLIX1 worked where temozolomide did not *Data to be presented @ future conferences $BLRX finance.yahoo.com/sectors/health…

@syndevrx holds over 60 patents for evexomostat that include composition of matter & methods of use. Chief Business Officer Jim Shanahan examines the ways SynDevRx has protected its IP. #BioPharma #EmergingBiotech #ClinicalResearch #LifeSciences youtube.com/shorts/uKFKSmz…

@LexariaBioCorp is working on the next generation of GLP-1 agonist products including amycretin and retatrutide to evaluate whether or not they are compatible with DehydraTECH. $LEXX CEO Richard Christopher explains. lexariabioscience.com/2026/04/23/lex… youtube.com/shorts/JDBMsSp… #OralGLP1

Chief Executive Officer Brad Carver & Chief Business Officer James Shanahan outline the goals for @syndevrx' clinical trials evaluating evexomostat. youtu.be/-iC3bWDE6_U #BioPharma #EmergingBiotech #ClinicalResearch #LifeSciences

DehydraTECH is used in tablets for the first time. @LexariaBioCorp CEO Richard Christopher discusses GLP-1 Human Study #7 that will evaluate DehydraTECH semaglutide tablet & capsule formulations to Wegovy tablets. $LEXX youtube.com/shorts/EdLtQmf… #OralGLP1 #GLP1Innovation #MetabolicTherapy

@LexariaBioCorp CEO Richard Christopher shares the details of Human Study #7. It is a 5-week, 3-arm design to assess safety, tolerability & PK properties that will compare Novo's SNAC DehydraTECH semaglutide tablet & capsule formulations to Wegovy tablets. $LEXX youtube.com/shorts/W9VXzLk… #OralGLP1

GeoVax reports 1Q *Preparation activities ongoing for Ph3 GEO-MVA trial ~CRO selection ~Trial infrastructure activation *Planned enrollment of 500 *Revs of $1.6mm *Net loss of $5.3mm $GOVX finance.yahoo.com/sectors/health…

Cardiff Oncology report 1Q *FDA End of Ph2 meeting complete *Detailed $CRDF 004 data @ascocancer.bsky.social *New CFO & COO *Cash of $46mm finance.yahoo.com/sectors/health…

@CingulateInc reports 1Q *Cash of $26mm *Responding to FDA info requests *Pre-commercialization efforts ongoing $CING finance.yahoo.com/sectors/health…

@DyadicInc reports 1Q *Revs of $1.1mm vs our $1.0mm *Loss of 5c matches our ests *Call @ 5 pm ET $DYAI dyadic.com/dyadic-announc…